Citadel Advisors’s Syneos Health, Inc. Class A Common Stock SYNH Stock Holding History

Citadel Advisors’s Portfolio SYNH Stock Details SYNH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-33,500	Closed	-$1.41M	–	15465
2023 Q2	$1.41M	Sell	33,500 -754,045	-96%	-$30.5M	﹤0.01%	5784
2023 Q1	$28.1M	Buy	787,545 +673,615	+591%	+$24.4M	0.01%	1597
2022 Q4	$4.18M	Sell	113,930 -77,051	-40%	-$3.05M	﹤0.01%	4165
2022 Q3	$9.01M	Sell	190,981 -610,256	-76%	-$39.4M	﹤0.01%	2924
2022 Q2	$57.4M	Buy	801,237 +373,503	+87%	+$27.3M	0.01%	912
2022 Q1	$34.6M	Buy	+427,734	New	+$36.2M	0.01%	1410
2021 Q3	–	Sell	-522,690	Closed	-$47.3M	–	14950
2021 Q2	$46.8M	Sell	522,690 -214,337	-29%	-$18.1M	0.01%	1181
2021 Q1	$55.9M	Sell	737,027 -1,296,430	-64%	-$97.7M	0.01%	962
2020 Q4	$139M	Buy	2,033,457 +823,393	+68%	+$51.3M	0.04%	397
2020 Q3	$64.3M	Buy	1,210,064 +215,419	+22%	+$12.8M	0.02%	700
2020 Q2	$57.9M	Buy	994,645 +117,932	+13%	+$6.34M	0.02%	712
2020 Q1	$34.6M	Buy	876,713 +853,299	+3,644%	+$49.9M	0.02%	834
2019 Q4	$1.39M	Sell	23,414 -8,046	-26%	-$433K	﹤0.01%	5000
2019 Q3	$1.67M	Buy	31,460 +2,765	+10%	+$142K	﹤0.01%	4780
2019 Q2	$1.47M	Sell	28,695 -16,927	-37%	-$788K	﹤0.01%	5061
2019 Q1	$2.36M	Sell	45,622 -26,657	-37%	-$1.29M	﹤0.01%	4184
2018 Q4	$2.84M	Sell	72,279 -233,979	-76%	-$10.9M	﹤0.01%	3602
2018 Q3	$15.8M	Sell	306,258 -738,665	-71%	-$36.2M	0.01%	1611
2018 Q2	$49M	Buy	1,044,923 +831,686	+390%	+$34.4M	0.02%	718
2018 Q1	$7.57M	Sell	213,237 -38,120	-15%	-$1.49M	﹤0.01%	2001
2017 Q4	$11M	Buy	251,357 +138,235	+122%	+$6.46M	0.01%	1637
2017 Q3	$5.92M	Buy	113,122 +100,884	+824%	+$5.63M	﹤0.01%	2126
2017 Q2	$716K	Sell	12,238 -409,332	-97%	-$21.3M	﹤0.01%	4601
2017 Q1	$19.3M	Buy	421,570 +360,073	+586%	+$17.9M	0.02%	977
2016 Q4	$3.23M	Sell	61,497 -414,722	-87%	-$20.1M	﹤0.01%	2414
2016 Q3	$21.2M	Buy	476,219 +158,317	+50%	+$6.87M	0.02%	838
2016 Q2	$12.1M	Sell	317,902 -330,859	-51%	-$14.5M	0.01%	1089
2016 Q1	$26.7M	Sell	648,761 -543,101	-46%	-$22.4M	0.03%	582
2015 Q4	$57.8M	Buy	1,191,862 +642,274	+117%	+$28.6M	0.06%	337
2015 Q3	$22M	Buy	549,588 +240,129	+78%	+$10.5M	0.02%	835
2015 Q2	$12.4M	Buy	309,459 +42,678	+16%	+$1.47M	0.01%	1322
2015 Q1	$8.73M	Sell	266,781 -29,005	-10%	-$801K	0.01%	1568
2014 Q4	$7.6M	Buy	+295,786	New	+$7.04M	0.01%	1620

Other funds holding SYNH

Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Natixis Advisors Boston, Massachusetts $71.9B AUM 28.03% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Nomura Asset Management Tokyo, Japan $38.8B AUM 30.94% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

CFB

Cullen/Frost Bankers San Antonio, Texas $8.81B AUM 22.47% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citadel Advisors's SYNH Position: Q3 2023 in Review

Citadel Advisors sold out of Syneos Health, Inc. Class A Common Stock (SYNH) in Q3 2023, closing a stake of 33,500 shares — an estimated $1.41M sold.

Citadel Advisors first reported a position in SYNH in Q4 2014 and held it in 33 quarters. The position peaked at $139M in Q4 2020. 10 funds tracked by Wall St. Rank hold SYNH as of Q3 2023.

Citadel Advisors reported no remaining Syneos Health, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Citadel Advisors sold 33,500 Syneos Health, Inc. Class A Common Stock shares in Q3 2023, an estimated $1.41M.
Citadel Advisors first reported a position in Syneos Health, Inc. Class A Common Stock in Q4 2014 and held it in 33 quarters.
Citadel Advisors's Syneos Health, Inc. Class A Common Stock position peaked at $139M in Q4 2020.
10 funds tracked by Wall St. Rank held Syneos Health, Inc. Class A Common Stock as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.